Cargando…

Previous Infection Combined with Vaccination Produces Neutralizing Antibodies with Potency against SARS-CoV-2 Variants

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to evolve in humans. Spike protein mutations increase transmission and potentially evade antibodies raised against the original sequence used in current vaccines. Our evaluation of serum neutralizing activity in both persons soon...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ibarrondo, F. Javier, Hofmann, Christian, Ali, Ayub, Ayoub, Paul, Kohn, Donald B., Yang, Otto O.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Microbiology 2021
Materias:	Observation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8649753/ https://www.ncbi.nlm.nih.gov/pubmed/34872349 http://dx.doi.org/10.1128/mBio.02656-21

Ejemplares similares

Potency of Fusion-Inhibitory Lipopeptides against SARS-CoV-2 Variants of Concern
por: Schmitz, Katharina S., et al.
Publicado: (2022)

Neutralization of SARS-CoV-2 Variants of Concern Harboring Q677H
por: Zeng, Cong, et al.
Publicado: (2021)

B.1.526 SARS-CoV-2 Variants Identified in New York City are Neutralized by Vaccine-Elicited and Therapeutic Monoclonal Antibodies
por: Zhou, Hao, et al.
Publicado: (2021)

High-Titer Neutralizing Antibodies against the SARS-CoV-2 Delta Variant Induced by Alhydroxyquim-II-Adjuvanted Trimeric Spike Antigens
por: Counoupas, Claudio, et al.
Publicado: (2022)

Ancestral SARS-CoV-2-Driven Antibody Repertoire Diversity in an Unvaccinated Individual Correlates with Expanded Neutralization Breadth
por: Deshpande, Suprit, et al.
Publicado: (2023)

Dual Monoclonal Antibodies on Sars-Cov-2 Alpha and Delta Variants: Clinical and Virological Efficacy
por: Ferré, Valentine Marie, et al.
Publicado: (2022)

Neutralization Titers in Vaccinated Patients with SARS-CoV-2 Delta Breakthrough Infections
por: Zou, Jing, et al.
Publicado: (2022)

Transmission of NDM-5-Producing and OXA-48-Producing Escherichia coli Sequence Type 648 by International Visitors without Previous Medical Exposure
por: Harada, Sohei, et al.
Publicado: (2021)

Antibody Neutralization of HIV-1 Crossing the Blood-Brain Barrier
por: Lorin, Valérie, et al.
Publicado: (2020)

The neutralization potency of anti-SARS-CoV-2 therapeutic human monoclonal antibodies is retained against viral variants
por: Makdasi, Efi, et al.
Publicado: (2021)

SARS-CoV-2 B.1.1.7 Decline Is Not Driven by the Introduction of a More Successful Variant
por: Rodríguez-Grande, Cristina, et al.
Publicado: (2021)

Neutralization Mechanisms of Two Highly Potent Antibodies against Human Enterovirus 71
por: Zhu, Ling, et al.
Publicado: (2018)

Production of two SARS-CoV-2 neutralizing antibodies with different potencies in Nicotiana benthamiana
por: Frigerio, Rachele, et al.
Publicado: (2022)

Role of Zika Virus Envelope Protein Domain III as a Target of Human Neutralizing Antibodies
por: Gallichotte, Emily N., et al.
Publicado: (2019)

Assessing Multiplex Tiling PCR Sequencing Approaches for Detecting Genomic Variants of SARS-CoV-2 in Municipal Wastewater
por: Lin, Xuan, et al.
Publicado: (2021)

Previously infected vaccinees broadly neutralize SARS-CoV-2 variants
por: Leier, Hans C., et al.
Publicado: (2021)

Novel sarbecovirus bispecific neutralizing antibodies with exceptional breadth and potency against currently circulating SARS-CoV-2 variants and sarbecoviruses
por: Wang, Yingdan, et al.
Publicado: (2022)

Temporal maturation of neutralizing antibodies in COVID-19 convalescent individuals improves potency and breadth to circulating SARS-CoV-2 variants
por: Moriyama, Saya, et al.
Publicado: (2021)

Temsavir Treatment of HIV-1-Infected Cells Decreases Envelope Glycoprotein Recognition by Broadly Neutralizing Antibodies
por: Boutin, Marianne, et al.
Publicado: (2022)

Development of potency, breadth and resilience to viral escape mutations in SARS-CoV-2 neutralizing antibodies
por: Muecksch, Frauke, et al.
Publicado: (2021)

Tetravalent SARS-CoV-2 Neutralizing Antibodies Show Enhanced Potency and Resistance to Escape Mutations
por: Miersch, Shane, et al.
Publicado: (2021)

Engineering SARS-CoV-2 neutralizing antibodies for increased potency and reduced viral escape pathways
por: Zhao, Fangzhu, et al.
Publicado: (2022)

Impaired potency of neutralizing antibodies against cell–cell fusion mediated by SARS-CoV-2
por: Wang, Qian, et al.
Publicado: (2023)

Decreased Sensitivity of Rapid Antigen Test Is Associated with a Lower Viral Load of Omicron than Delta SARS-CoV-2 Variant
por: Cocherie, Théophile, et al.
Publicado: (2022)

Evidence for an ACE2-Independent Entry Pathway That Can Protect from Neutralization by an Antibody Used for COVID-19 Therapy
por: Hoffmann, Markus, et al.
Publicado: (2022)

Shared Mutations in Emerging SARS-CoV-2 Circulating Variants May Lead to Reverse Transcription-PCR (RT-PCR)-Based Misidentification of B.1.351 and P.1 Variants of Concern
por: Losada, Carmen, et al.
Publicado: (2021)

Detecting Waning Serological Response with Commercial Immunoassays: 18-Month Longitudinal Follow-up of Anti-SARS-CoV-2 Nucleocapsid Antibodies
por: Nakagama, Yu, et al.
Publicado: (2022)

Two human monoclonal SARS-CoV-2 antibodies that maintain neutralizing potency against the SARS-CoV-2 Omicron BA.1 and BA.2 variants
por: Zheng, Qianqian, et al.
Publicado: (2022)

Rapid Detection of the Omicron (B.1.1.529) SARS-CoV-2 Variant Using a COVID-19 Diagnostic PCR Assay
por: Ippoliti, Chiara, et al.
Publicado: (2022)

Minimal Crossover between Mutations Associated with Omicron Variant of SARS-CoV-2 and CD8(+) T-Cell Epitopes Identified in COVID-19 Convalescent Individuals
por: Redd, Andrew D., et al.
Publicado: (2022)

Engineering SARS-CoV-2 cocktail antibodies into a bispecific format improves neutralizing potency and breadth
por: Ku, Zhiqiang, et al.
Publicado: (2022)

SARS-CoV-2 Distribution in Residential Housing Suggests Contact Deposition and Correlates with Rothia sp.
por: Cantú, Victor J., et al.
Publicado: (2022)

Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant
por: Graham, Carl, et al.
Publicado: (2021)

Polyclonal F(ab’)(2) fragments of equine antibodies raised against the spike protein neutralize SARS-CoV-2 variants with high potency
por: Cunha, Luis Eduardo R., et al.
Publicado: (2021)

Bispecific VH/Fab antibodies targeting neutralizing and non-neutralizing Spike epitopes demonstrate enhanced potency against SARS-CoV-2
por: Lim, Shion A., et al.
Publicado: (2021)

Strong Neutralizing Antibody Responses to SARS-CoV-2 Variants Following a Single Vaccine Dose in Subjects With Previous SARS-CoV-2 Infection
por: Ekström, Nina, et al.
Publicado: (2022)

Replicative Fitness of a SARS-CoV-2 20I/501Y.V1 Variant from Lineage B.1.1.7 in Human Reconstituted Bronchial Epithelium
por: Touret, Franck, et al.
Publicado: (2021)

Comparison of potency assays to assess SARS-CoV-2 neutralizing antibody capacity in COVID-19 convalescent plasma
por: von Rhein, Christine, et al.
Publicado: (2021)

Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations
por: Muecksch, Frauke, et al.
Publicado: (2021)

Monospecific and bispecific monoclonal SARS-CoV-2 neutralizing antibodies that maintain potency against B.1.617
por: Peng, Lei, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_7trvcm6ck69pns4s2g2m7um70m